Why remdesivir may not be a wonder drug

Gilead’s $1,000-a-pill antiviral remdesivir is no wonder drug. We knew this when it failed for hepatitis, the disease it was created for. And then when it  failed for Ebola. And then again, when it failed for COVID-19. But like a bolt, in late April, a breakthrough: in a second trial for COVID-19 patients, remdesivir sped time to […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.

Source: Kevin, M.D. - Medical Weblog - May 31, 2020 Category: General Medicine Authors: < span itemprop="author" > < a href="https://www.kevinmd.com/blog/post-author/daniel-hopkins" rel="tag" > Daniel Hopkins, MD < /a > < /span > Tags: Meds COVID-19 coronavirus Infectious Disease Source Type: blogs